valuationLAB research is available on Bloomberg Terminal®
Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
For more information, go to bloomberg.com/professional.
valuationLAB research is available on Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges.
For more information, go to financial.thomsonreuters.com.
valuationLAB research is available on Evaluate
Evaluate Ltd. provides trusted commercial intelligence for the pharmaceutical industry and their advisors — including market leading consensus sales forecasts, detailed company financials, comprehensive product portfolios, proprietary predictive analytics and more — for seamless, comprehensive view of the global pharmaceutical market.
Evaluate has been a partner to industry-leading organizations for over 20 years, including 90% of the top 50 pharma companies. For more information on how we radically transform our clients’ confidence in strategic decisions, visit www.evaluate.com.
Austin Life Science Partners (Austin LSP) is part of the Austin BFP Group. Together we support more than 3.000 clients, in regional, domestic and international markets with more than 150 employees at 5 offices in Austria and Switzerland.
We are a dynamic advisory company offering a comprehensive range of services in corporate finance & funding, business development, business partnering and, management consulting for MedTech, Digital Health and BioTech companies.
For more information, go to austin-lsp.com.
Welcome to the Swiss Financial Analysts Association SFAA, the association for financial and investment fund analysts, asset managers, investment advisors, portfolio managers, wealth and relationship managers. The association was set up in 1962 and now has more than 2600 members.
For more information, go to sfaa.ch.
Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.
The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.
Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.
For more information, go to swissbiotech.org.